Tirzepatide adds hepatoprotection to its armoury

In The Lancet Diabetes & Endocrinology, Amalia Gastaldelli and colleagues 1 Gastaldelli A Cusi K Fernández Landó L Bray R Brouwers B Rodriíguez A Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022; (published online April 22.)https://doi.org/10.1016/S2213-8587(22)00070-5 Summary Full Text Full Text PDF PubMed Scopus (18) Google Scholar present their findings from SURPASS-3 MRI, a substudy of the randomised, open-label, parallel-group, phase-3 SURPASS-3 trial. 2 Ludvik B Giorgino F Jódar E et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021; 398: 583-598 Summary Full Text Full Text PDF PubMed Scopus (77) Google Scholar It is the first study to date to assess the effect of a 52-week treatment with subcutaneous tirzepatide administered once per week versus subcutaneous insulin degludec administered once per day on liver fat content (LFC) in adults with inadequately controlled type-2 diabetes. A total of 296 participants without a history of significant alcohol consumption were randomly assigned to active treatment (tirzepatide 5 mg, n=71; tirzepatide 10 mg, n=79; tirzepatide 15 mg, n=72; insulin degludec, n=74). The primary efficacy endpoint was the change from baseline in LFC as assessed by MRI-proton density fat fraction (MRI-PDFF) at week 52, using pooled data from tirzepatide 10 mg and 15 mg versus insulin degludec. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trialTirzepatide showed a significant reduction in LFC and VAT and ASAT volumes compared with insulin degludec in this subpopulation of patients with type 2 diabetes in the SURPASS-3 study. These data provide additional evidence on the metabolic effects of this novel dual GIP and GLP-1 receptor agonist. Full-Text PDF